Evidence map›Paper›PMID 32260077›Full record

ArticleCancers2020

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.

Tashbib Khan, Yaowu He, Thomas Kryza, Brittney S Harrington, Jennifer H Gunter, Mitchell A Sullivan, Tahleesa Cuda, Rebecca Rogers, Claire M Davies, Amy Broomfield and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Interplay between altered metabolism and DNA damage and repair in ovarian cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy.Frontiers in cell and developmental biology · 2021
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 2 countries.

Tashbib KhanMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0001-5203-0672
Yaowu HeMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Thomas KryzaMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Brittney S HarringtonMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Jennifer H GunterAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.ORCID 0000-0003-2447-5732
Mitchell A SullivanMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Tahleesa CudaMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Rebecca RogersMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Claire M DaviesMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Amy BroomfieldMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia.
Madeline GoughMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia.
Andy C WuMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0002-0864-4447
Thomas McGannMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0002-7699-1010
S John WerohaDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Paul HaluskaDepartment of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Josephine M ForbesMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0002-5595-8174
Jane E ArmesMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Sinead C BarryMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Jermaine I CowardMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Nisha JagasiaMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia.
Naven ChettyMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia.
Cameron E SnellMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Rohan LourieMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Lewis C PerrinMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
John D HooperMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0003-1054-8486
Translational Research Institute · AUMater Health Services · AUBristol-Myers Squibb (United States) · USMayo Clinic in Arizona · US

Funding

Australia New Zealand Gynaecological Oncology Group NAMater Foundation NAMater Foundation McGuckin Early Career Fellowship NAUniversity of Queenslad Amplify Initiative NAUniversity of Queensland Graduate School NA
6 · The paper itself

Abstract

High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses-of more than 10-fold lower than previously reported for other cancers-significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.

Indexed as

2DGclear cell ovarian cancerglycogen

Identifiers

PMID32260077
PMCPMC7226162
OpenAlexW3014375791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.